The Addario Lung Cancer Medical Institute (ALCMI) and Scancell Holdings have partnered to evaluate Scancell's cancer vaccine SCIB2 in a Phase I/II trial to treat non-small-cell lung cancer (NSCLC).
SCIB2 is a vaccine designed to stimulate immune responses to specific lung cancer antigens and help the body to target and fight NSCLC.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The vaccine has been developed as part of Scancell's ImmunoBody cancer vaccine platform, a new immunotherapy treatment under development that activates the immune system to treat and prevent cancer.
It stimulates both the helper cell system and the cytotoxic T-lymphocyte part of the immune system.
Scancell chief executive officer Richard Goodfellow said: "We have generated preclinical data that suggests that SCIB2 could be the ideal complement to existing and emerging checkpoint inhibitor therapies to treat NSCLC and so provide an effective new potential treatment option for patients with this devastating disease."
The firm has claimed to have successfully completed a Phase I/II clinical trial of SCIB1 in patients with melanoma.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe results showed that SCIB1 monotherapy effects tumour load, generates a melanoma-specific immune response and showed a survival trend without serious side effects.
Pre-clinical data on SCIB1 or SCIB2 combination therapy and checkpoint inhibition have indicated increased tumour destruction and longer survival times in comparison to monotherapy.
ALCMI is expected to begin next year and intends to aid Scancell in the design and development of a Phase I/II clinical trial of SCIB2 in patients with NSCLC.
